November 5, 2025 — Viridian Therapeutics Inc. (VRDN) reported its third-quarter financial results, highlighting a public equity offering, royalty financing with DRI Healthcare Acquisitions LP, and an amended agreement with Hercules Capital, Inc.
Viridian President and CEO Steve Mahoney said the company’s comprehensive financing package, which includes raising equity and royalty financing, is expected to lead to profitability. The company is preparing for the commercial launch of veligrotug by mid-2026, pending FDA approval under Priority Review. The company has also submitted a Marketing Authorization Application to the European Medicines Agency, and is on track to complete enrollment in phase 3 clinical trials for VRDN-003. The company is focused on the market for Thyroid Eye Disease.
Key financial results show research and development expenses at $86.3 million for the quarter, and general and administrative expenses were $24.3 million. Viridian had 100,898,358 shares of common stock outstanding as of September 30, 2025. The company believes its current cash will fund current business plans through profitability.
Viridian will be participating in investor conferences including the Stifel 2025 Healthcare Conference on November 12, the Jefferies Global Healthcare Conference on November 19, and the Evercore Healthcare Conference on December 4.
Contact:
For more information, please visit www.viridiantherapeutics.com.
Source: Viridian Therapeutics, Inc.
